First-pass extracted concept

amyloid hypothesis

Candidate: concept label2 source documents5 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Evidence Snippets

The amyloid hypothesis of Alzheimer's disease at 25 years

The supplied review summary states that the review covers major lines of evidence for Aβ toxicity and APP/presenilin mutations, and the citation scaffold explicitly links the review to foundational genetics and the amyloid hypothesis.

Evidence 2Source 2DOI PubMedprovenance

Supporting Sources

Source 1review2016EMBO Molecular MedicineDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Source 2review2008Journal of Biological ChemistryDOI PubMed

1 evidence snippet 2 linked claims Claim 1 Claim 2

Linked Claims

Claim 1disease timing modelsupports2016Source 1DOI PubMed

The review presents biomarker evidence that amyloid abnormalities precede clinical symptoms by decades in dominantly inherited Alzheimer's disease.

Quoted textsource-backed

directly supports the review’s claim that amyloid abnormalities precede symptoms by decades

Claim 2evidence taxonomysupports2016Source 1DOI PubMed

The review organizes support for the amyloid hypothesis around APP gene dosage and protective APP variation, APOE-linked amyloid-beta clearance, biomarker timing in dominantly inherited Alzheimer's disease, and microglial or endocytic modulators of amyloid-beta handling including CD33, TREM2, ABCA7, and PICALM.

Quoted textsource-backed

The review explicitly organizes support for the amyloid hypothesis around several evidence classes: APP gene dosage and protective APP variation, APOE-linked Aβ clearance, biomarker timing in dominantly inherited AD, and microglial/endocytic modulators of Aβ handling including CD33, TREM2, ABCA7, and PICALM.

Claim 3review scope summarysupports2016Source 1DOI PubMed

This review synthesizes evidence supporting the amyloid hypothesis of Alzheimer's disease from genetics, biomarker timing, and amyloid-beta handling mechanisms.

Claim 4genetic pathogenesis summarysupports2008Source 2DOI PubMed

The review synthesizes genetic evidence that APP and presenilin mutations support a pathogenic role for altered Aβ production, including increased Aβ42.

Claim 5review summarysupports2008Source 2DOI PubMed

The review presents soluble amyloid-β oligomers as central toxic species in Alzheimer disease pathogenesis rather than focusing only on insoluble plaque deposits.